7 Feb 2017 07:02
Â
Â
Motif Bio plc
("Motif Bio" or the "Company")
Â
Notification and public disclosure of transactions by PDMR and persons closely associated with them
Â
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 6 February 2017 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 14,500,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge"). In total, Amphion has pledged 42,461,625 ordinary shares in the Company in relation to the Share Pledge. As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the "Amphion Directors"). Amphion is therefore a "Person Closely Associated" with the Amphion Directors under the Market Abuse Regulation. The Share Pledge does not change the number of ordinary shares of the Company in issue.
Â
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
  |  | ||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name  | Amphion Innovations Plc | |||||
2 | Reason for the notification | ||||||
a) | Position/status  | Person Closely Associated with PDMRs of Motif Bio Plc (Robert Bertoldi and Richard Morgan) | |||||
b) | Initial notification/Amendment  | Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name | Motif Bio Plc | |||||
b) | LEI | 54930080DN00QTIUUU84 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument  Identification code | Ordinary Shares  ISIN GB00BVVT4H71 | |||||
b) | Nature of the transaction  | Transfer of the legal but not beneficial interest in 14,500,000 Ordinary Shares by way of a pledge for a loan  | |||||
c) | Price(s) and volume(s) Â Â |
| |||||
d) | Aggregated information  |
| |||||
e) | Date of the transaction  | 6 February 2017  | |||||
f) | Place of the transaction   | N/A | |||||
Â
For further information please contact:
Â
Motif Bio plc | info@motifbio.com | |
Graham Lumsden (Chief Executive Officer) | Â | |
 |  | |
Zeus Capital Limited (NOMAD & BROKER) | +44 (0)20 3829 5000 | |
Phil Walker/Giles Balleny | Â | |
Dominic Wilson | Â | |
 |  | |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6600 | |
Patrick Claridge/ David Hignell | Â | |
John Howes/ Rob Rees (Broking) | Â | |
 |  | |
Walbrook PR Ltd. (FINANCIAL PR & IR) | +44 (0) 20 7933 8780 or motifbio@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Mike Wort | Mob: +44 (0)7900 608 002 | |
 |  | |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
Raimund Gabriel | Â | |
Â
Â
Â